Pharma BD Deal Intelligence

Mallinckrodt plc / Therakos, Inc.

2015 · Acquisition/Merger · $1.3B · Complete

Announcement Sentiment

Neutral / mixed

Mallinckrodt acquired Therakos from The Gores Group for approximately $1.325B, adding the global leader in autologous immune cell therapy via extracorporeal photopheresis. Closed September 28, 2015. Mallinckrodt later divested Therakos to CVC Capital for $925M (2021).

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Assets Advanced

Assessment window: 10yr post-close.

Key facts

Announced Aug 11, 2015
Closed Sep 28, 2015
Deal value $1.3B
Deal type Acquisition/Merger
Therapeutic area Cutaneous T-cell lymphoma (CTCL); off-label graft-versus-host disease, transplant rejection
Indications Cutaneous T-cell lymphoma (CTCL); off-label graft-versus-host disease, transplant rejection
Key assets THERAKOS extracorporeal photopheresis (ECP) immunotherapy platform (UVAR XTS, CELLEX)
Mechanism Autologous immune cell therapy via extracorporeal photopheresis (drug-device combination)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals